Skyrizi (risankizumab) vs Zoryve (roflumilast)
Skyrizi (risankizumab) vs Zoryve (roflumilast)
Skyrizi (risankizumab) is a biologic medication that targets interleukin-23 (IL-23), an important molecule involved in the inflammatory process of conditions like psoriasis, and is administered via injection. Zoryve (roflumilast), on the other hand, is a phosphodiesterase 4 (PDE4) inhibitor that comes in a topical cream form and is used to reduce inflammation and plaque buildup associated with psoriasis. When deciding between the two, it is crucial to consider factors such as the severity of the condition, preferred route of administration, and the patient's medical history, as Skyrizi is typically used for moderate to severe plaque psoriasis, while Zoryve is used for mild to moderate cases.
Difference between Skyrizi and Zoryve
Metric | Skyrizi (risankizumab) | Zoryve (roflumilast) |
---|---|---|
Generic name | Risankizumab | Roflumilast |
Indications | Plaque psoriasis, Psoriatic arthritis | Plaque psoriasis |
Mechanism of action | Interleukin-23 antagonist | Phosphodiesterase 4 (PDE4) inhibitor |
Brand names | Skyrizi | Zoryve |
Administrative route | Subcutaneous injection | Topical |
Side effects | Upper respiratory infections, headache, fatigue, injection site reactions | Diarrhea, headache, nausea, abdominal pain, decreased appetite, insomnia |
Contraindications | Known hypersensitivity to risankizumab or excipients | Known hypersensitivity to roflumilast or any component of the product |
Drug class | Monoclonal antibody | Small molecule |
Manufacturer | AbbVie | Arcutis Biotherapeutics |
Efficacy
Skyrizi (Risankizumab) Efficacy in Psoriasis
Skyrizi, which contains the active ingredient risankizumab, is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Clinical trials have demonstrated that Skyrizi is highly effective in achieving clear or almost clear skin. In pivotal phase 3 studies, such as the UltIMMa-1 and UltIMMa-2 trials, a significant proportion of patients treated with Skyrizi achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) score, which is considered a robust measure of efficacy in psoriasis treatment.
The long-term efficacy of Skyrizi has also been evaluated, showing sustained skin clearance over time. The majority of patients who responded to Skyrizi during the initial 16 weeks of treatment maintained their PASI 90 response through one year, with continued treatment every 12 weeks. This sustained response is crucial for patients with psoriasis, as it is a chronic condition that requires long-term management.
Zoryve (Roflumilast) Efficacy in Psoriasis
Zoryve, with the active ingredient roflumilast, is a phosphodiesterase-4 (PDE4) inhibitor. While it is not yet approved by the FDA for the treatment of psoriasis, roflumilast has been studied for its potential off-label use in this condition. In clinical trials, topical formulations of roflumilast have shown promise in reducing the symptoms of plaque psoriasis. The efficacy of roflumilast cream has been evaluated in phase 2 and phase 3 clinical trials, where it has demonstrated significant improvements in PASI scores compared to placebo.
Moreover, roflumilast has been found to be well-tolerated with a favorable safety profile in clinical studies, which is an important consideration for the long-term management of a chronic condition like psoriasis. The potential of Zoryve as a treatment for psoriasis lies in its anti-inflammatory properties, targeting an enzyme involved in the inflammatory pathway that contributes to the pathogenesis of psoriasis. Further research and clinical trials are needed to fully establish the efficacy and safety of roflumilast for psoriasis, and to potentially support its approval for this indication.
Regulatory Agency Approvals
Skyrizi
Zoryve
Access Skyrizi or Zoryve today
If Skyrizi or Zoryve are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us